bf/NASDAQ:AGLE_icon.jpeg

NASDAQ:AGLE

Aeglea BioTherapeutics, Inc.

  • Stock

USD

Last Close

11.26

27/11 21:00

Market Cap

48.63M

Beta: 1.76

Volume Today

43.24K

Avg: 725.60K

PE Ratio

−0.18

PFCF: −0.56

Preview

Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page

Subscribe NowHelp
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
average inventory
-407.50K
-
-407.50K
0%
average payables
268K
-
247.50K
7.65%
172K
30.51%
278.50K
61.92%
526K
88.87%
1.91M
262.83%
2.70M
41.68%
2.79M
3.05%
2.00M
28.30%
786.50K
60.64%
average receivables
848.50K
-
1.46M
71.60%
2.15M
47.42%
1.54M
28.30%
407.50K
-
595K
46.01%
187.50K
68.49%
book value per share
0.27
-
3.16
1,050.79%
6.43
103.58%
3.33
48.26%
3.24
2.68%
1.88
41.93%
2.62
39.32%
1.28
51.27%
0.60
53.25%
25.07
4,100.09%
capex per share
-0.03
-
-0.02
31.43%
-0.02
18.97%
-0.04
88.98%
-0.02
50.47%
-0.05
130.42%
-0.08
71.72%
-0.01
89.13%
-0.00
94.83%
capex to depreciation
-9.53
-
-2.34
75.47%
-1.61
31.28%
-2.49
54.79%
-1.44
42.06%
-3.57
147.83%
-4.30
20.39%
-0.36
91.54%
-0.02
93.33%
capex to operating cash flow
0.02
-
0.02
23.25%
0.01
40.59%
0.03
123.48%
0.01
47.87%
0.02
73.26%
0.06
148.69%
0.01
81.11%
0.00
95.56%
capex to revenue
-0.03
-
-0.05
34.01%
-0.12
159.61%
-0.11
8.73%
-0.03
-
-0.02
46.64%
cash per share
0.38
-
2.89
654.12%
6.49
124.20%
3.32
48.73%
3.58
7.63%
2.25
37.07%
2.74
21.70%
1.42
48.31%
0.66
53.33%
46.22
6,892.42%
days of inventory on hand
days payables outstanding
339.25
-
days sales outstanding
101.79
-
95.82
5.86%
215.84
125.25%
15.87
-
58.77
270.21%
debt to assets
0.05
-
0.09
72.98%
0.06
-
0.03
44.62%
0.05
36.12%
0.07
41.80%
0.25
280.14%
debt to equity
0.06
-
0.10
80.93%
0.08
-
0.04
53.77%
0.06
54.23%
0.09
53.14%
0.46
399.35%
dividend yield
earnings yield
-0.01
-
-0.00
34.86%
-0.02
403.64%
-0.01
34.67%
-0.01
14.55%
-0.01
9.05%
-0.01
38.35%
-0.01
10.22%
-0.09
948.82%
-2.14
2,326.24%
enterprise value
1.66B
-
2.76B
66.09%
1.02B
63.18%
2.03B
99.91%
3.88B
90.66%
6.09B
57.05%
10.42B
71.09%
7.80B
25.15%
917.92M
88.23%
53.63M
94.16%
enterprise value over ebitda
-223.52
-
-246.08
10.09%
-47.16
80.83%
-75.34
59.75%
-87.99
16.79%
-75.79
13.87%
-129.42
70.77%
-118.77
8.23%
-10.83
90.88%
-0.42
96.13%
ev to operating cash flow
-226.75
-
-251.54
10.94%
-53.99
78.54%
-82.60
53.01%
-120.42
45.78%
-92.68
23.04%
-137.46
48.32%
-145.15
5.59%
-11.45
92.11%
-0.54
95.31%
ev to sales
453.98
-
219.77
51.59%
390.64
77.75%
997.06
155.24%
416.09
-
394.13
5.28%
60.53
84.64%
free cash flow per share
-1.10
-
-0.98
11.16%
-1.95
98.74%
-1.67
14.27%
-1.57
6.10%
-2.10
34.25%
-1.50
28.67%
-0.83
44.95%
-0.95
15.21%
-13.61
1,330.69%
free cash flow yield
-0.00
-
-0.00
11.16%
-0.02
346.37%
-0.01
31.07%
-0.01
32.17%
-0.01
31.61%
-0.01
30.75%
-0.01
8.79%
-0.08
1,116.12%
-0.63
647.92%
graham net net
0.23
-
2.78
1,117.30%
6.16
121.51%
3.10
49.71%
3.08
0.48%
1.53
50.41%
2.33
52.56%
1.02
56.08%
0.42
59.28%
24.72
5,826.08%
graham number
3.06
-
8.38
173.78%
17.91
113.66%
11.61
35.16%
12.46
7.30%
10.01
19.63%
9.42
5.94%
5.36
43.06%
3.65
31.85%
income quality
0.71
-
0.97
37.15%
0.87
10.70%
0.90
4.09%
0.73
19.68%
0.84
15.64%
0.94
11.59%
0.82
12.85%
0.96
17.13%
0.29
69.16%
intangibles to total assets
0
-
0
0
0
0
0
0
0
0
0
interest coverage
-101.29
-
interest debt per share
0.36
-
0.33
6.38%
0.16
-
0.10
35.59%
0.08
24.84%
0.06
15.47%
11.52
17,661.68%
inventory turnover
invested capital
0.06
-
0.10
80.93%
0.08
-
0.04
53.77%
0.06
54.23%
0.09
53.14%
309.55M
336,399,065,572.93%
market cap
1.67B
-
2.79B
67.59%
1.06B
61.86%
2.05B
92.15%
3.90B
90.56%
6.10B
56.51%
10.50B
72.08%
7.81B
25.65%
948.16M
87.86%
157.96M
83.34%
net current asset value
1.67M
-
35.74M
2,037.32%
62.33M
74.41%
49.25M
20.98%
66.36M
34.74%
51.40M
22.54%
128.00M
149.02%
72.91M
43.04%
41.42M
43.19%
183.69M
343.48%
net debt to ebitda
0.35
-
2.61
642.24%
2.21
15.15%
0.47
78.55%
0.51
7.35%
0.18
65.35%
1.05
495.41%
0.15
85.37%
0.36
131.84%
0.82
128.90%
net income per share
-1.52
-
-0.99
34.86%
-2.22
124.24%
-1.80
18.76%
-2.13
18.30%
-2.37
11.24%
-1.50
36.49%
-1.00
33.48%
-0.99
0.64%
-46.15
4,541.12%
operating cash flow per share
-1.08
-
-0.96
10.66%
-1.92
100.25%
-1.63
15.43%
-1.55
4.98%
-2.06
32.99%
-1.42
30.95%
-0.82
42.45%
-0.95
16.39%
-13.61
1,331.37%
payables turnover
1.08
-
receivables turnover
3.59
-
3.81
6.23%
1.69
55.60%
22.99
-
6.21
72.99%
research and ddevelopement to revenue
1.88
-
3.92
108.28%
4.38
11.81%
9.44
115.46%
3.05
-
25.15
725.88%
101.02
301.64%
return on tangible assets
-3.53
-
-0.29
91.73%
-0.32
10.72%
-0.49
50.11%
-0.57
17.46%
-0.91
59.51%
-0.50
45.40%
-0.60
20.48%
-1.18
96.81%
-0.99
15.88%
revenue per share
0.53
-
0.47
11.22%
0.34
27.21%
0.19
45.73%
0.29
-
0.03
90.30%
0.12
336.80%
roe
-5.53
-
-0.31
94.34%
-0.34
10.15%
-0.54
57.02%
-0.66
21.56%
-1.26
91.55%
-0.57
54.42%
-0.78
36.51%
-1.67
112.55%
-1.84
10.50%
roic
-5.42
-
-0.31
94.23%
-0.33
5.20%
-0.50
51.60%
-0.67
35.00%
-1.11
64.36%
-0.54
51.52%
-0.70
30.39%
-1.42
103.10%
-0.78
44.98%
sales general and administrative to revenue
0.98
-
1.81
85.52%
1.93
6.66%
3.25
68.00%
1.46
-
12.25
740.29%
45.09
268.04%
shareholders equity per share
0.27
-
3.16
1,050.79%
6.43
103.58%
3.33
48.26%
3.24
2.68%
1.88
41.93%
2.62
39.32%
1.28
51.27%
0.60
53.25%
25.07
4,100.09%
stock based compensation to revenue
0.13
-
0.26
109.31%
0.48
81.47%
1.10
129.93%
0.43
-
3.05
611.80%
28.98
849.11%
tangible asset value
1.87M
-
36.10M
1,828.63%
62.97M
74.40%
50.34M
20.06%
67.43M
33.95%
60.08M
10.90%
139.83M
132.74%
83.94M
39.97%
50.30M
40.07%
184.02M
265.80%
tangible book value per share
0.27
-
3.16
1,050.79%
6.43
103.58%
3.33
48.26%
3.24
2.68%
1.88
41.93%
2.62
39.32%
1.28
51.27%
0.60
53.25%
25.07
4,100.09%
working capital
1.67M
-
35.76M
2,038.94%
62.46M
74.65%
49.36M
20.97%
66.43M
34.58%
56.15M
15.48%
133.35M
137.50%
78.75M
40.95%
47.60M
39.55%
309.55M
550.29%

All numbers in USD (except ratios and percentages)